A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis

Keratosis, Actinic Clinical Trial

— TirbAKare  

Official title:

A Phase 3, Multicentre, Randomised, Double-blind, Vehicle-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tirbanibulin 10 mg/g Ointment Applied to a Treatment Field Larger Than 25 cm^2 and up to 100 cm^2 in Adult Patients With Actinic Keratosis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06135415
• Other study ID #: M-14867-33
• Secondary ID: 2023-505487-11
• Status: Recruiting
• Phase: Phase 3
• Start date: December 21, 2023
• Est. completion date: December 2024

Study information

• Verified date: April 2024
• Source: Almirall, S.A.
• Contact: Davide Carluccio
• Phone: +34607245217
• Email: gco[@]almirall.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the efficacy and safety of tirbanibulin 10 milligrams per gram (mg/g) ointment when applied to a treatment field (TF) larger than 25 centimeter square (cm^2) and up to 100 cm^2 in adult participants with actinic keratosis (AK).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 270
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants having a TF on the face or balding scalp (excluding lips, eyelids, and inside nostrils and ears) that contains >= 4 to less than or equal to (<=) 12 clinically typical, visible, and discrete (non-confluent) AK lesions and measures more than 25 cm2 (example, one cheek) and up to approximately 100 cm2 (example, mid face).
• Participants willing to avoid excessive sunlight or UV light exposure, including the use of tanning beds, to the face or scalp during the study.
• Women of childbearing potential (WOCBP), that is, fertile, defined as a female in the life period from menarche and until becoming post-menopausal (no menses for 12 months without an alternative medical cause) or permanently sterile (with hysterectomy, bilateral salpingectomy, or bilateral oophorectomy at least 3 months prior to screening) must have a negative urine pregnancy test using a highly sensitive method at screening and on Day 1 prior to treatment administration, be using highly effective methods of birth control for at least 30 days or 1 menstrual cycle, whichever is longer, and until at least 30 days or 1 menstrual period, whichever is longer, after the last dose of investigational product, agree to have pregnancy tests while in the study and at the end of the study, and agree not to be egg (oocyte) donors while on study and until at least 30 days or 1 menstrual period, whichever is longer, after the last dose of investigational product.
• Sexually active males with female partners who are WOCBP must agree to use two forms of contraception, one of which must be barrier contraception, from screening through 90 days after their last dose of study treatment. All non-sterile male participants must agree not to donate sperm or attempt conception from screening through 90 days following their last dose of study treatment.
• Participants should have ability to understand the purpose and risks of the trial, willingness and ability to comply with the protocol, and provided written informed consent in accordance with institutional and regulatory guidelines.

Exclusion Criteria:

• Participants with clinically atypical and/or rapidly changing AK lesions in the TF; hyperkeratotic or hypertrophic lesions, recalcitrant disease (defined as failure to respond to cryosurgery on 2 previous occasions) and/or cutaneous horn; history of invasive SCC, Bowen's disease, BCC, or other malignant tumors in the TF; any other dermatological disease that causes difficulty with examination.
• Location of the TF is on any location other than the face or balding scalp, within 5 centimeter (cm) of an incompletely healed wound, within 5 cm of a suspected BCC or other neoplasms, periorbital, lips, or nostrils.
• Participants having a previous treatment with tirbanibulin 10 mg/g ointment.
• Females who are pregnant or nursing or seeking to become pregnant.
• Participants having intention to use any concomitant medication that is not permitted by this protocol or failure to undergo the required washout period for a particular prohibited medication or therapy.
• Participants with anticipated need for inpatient hospitalization or inpatient surgery from Day 1 to Day 113.
• Participants with history of sensitivity and/or allergy to any of the ingredients in the study medication.
• Participants with significant abnormalities on the medical history, physical examination (PE) findings, vital signs, clinical chemistry, or hematology results that in the judgment of the investigator may interfere with the interpretation of the results.
• Participants with skin disease (example; atopic dermatitis, psoriasis, eczema) or condition (example; scarring, open wounds) that, in the opinion of the investigator, might interfere with the study conduct or evaluations, or which exposes the participant to unacceptable risk by study participation.
• Participants with significant uncontrolled or unstable medical diseases or conditions that, in the opinion of the investigator, would expose the participant to unacceptable risk by study participation.
• Participants who have participated in an investigational drug trial during which an investigational study medication was administered within 30 days or 5 half-lives of the investigational product, whichever is longer, before dosing in the current study.
• Participant who is employee or a relative to an employee at the research site or the Sponsor.

Related Conditions & MeSH terms

• Keratosis
• Keratosis, Actinic

Intervention

Drug:
• Tirbanibulin
Participants will apply tirbanibulin ointment topically on the face or balding scalp with AK.

Other:
• Vehicle ointment
Participants will apply vehicle ointment topically on the face or balding scalp with AK.

Locations

Country	Name	City	State
Germany	Site 1	Bad Bentheim
Germany	Site 3	Bochum
Germany	Site	Düsseldorf
Germany	Site 2	Hamburg
Germany	Site 4	Mahlow
Germany	Site 6	Wuppertal
Italy	Site 7	Roma
Poland	Site 10	Warsaw
Poland	Site 11	Warsaw
Poland	Site 9	Warsaw
Poland	Site 8	Wroclaw
Spain	Site 12	Barcelona
Spain	Site 13	Madrid
Spain	Site 14	Valencia
Spain	Site 15	Valencia
Spain	Site 16	Zaragoza

Sponsors (1)

Lead Sponsor	Collaborator
Almirall, S.A.

Countries where clinical trial is conducted

Germany,  Italy,  Poland,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent Change From Baseline in Lesion Count at Day 57	Percentage change from baseline in the AK lesion count will be assessed.	Baseline, Day 57
Secondary	Proportion of Participants With Partial Clearance (PC) at Day 57	PC is defined as proportion of participants achieving more than or equal to (>=) 75 percent (%) clearance of AK lesions in the TF on the face or scalp at Day 57.	At Day 57
Secondary	Proportion of Participants With Complete Clearance (CC) at Day 57	CC is defined as proportion of participants achieving 100 percent clearance of AK lesions in the TF on the face or scalp at Day 57.	At Day 57
Secondary	Proportion of Participants With Partial Clearance (PC) by Day 113		Baseline up to Day 113
Secondary	Proportion of Participants With Complete Clearance (CC) by Day 113		Baseline up to Day 113
Secondary	Total Number of Lesions per Participant in the TF at Specific Timepoints		Baseline, Day 8, 15, 29, 57, 64, 71, 85, and 113
Secondary	Percent Change From Baseline in lesion count in the TF at Specific Timepoints		Baseline, Day 8, 15, 29, 57, 64, 71, 85, and 113
Secondary	Number of New Lesions per Participant in the TF at Specific Timepoints	Number of new lesions that are not present at baseline, occurring per participant in the TF at specific timepoints will be assessed.	At Day 8, 15, 29, 57, 64, 71, 85, and 113
Secondary	Number of Baseline Lesions per Participant Present in the TF at Specific Timepoints	Number of lesions per participant in the TF at specific timepoints will be assessed.	Baseline, Day 8, 15, 29, 57, 64, 71, 85, and 113
Secondary	Change From Baseline in Skindex-16 Questionnaire Overall Score and Domain Scores (Symptoms, Emotions, and Functioning) at Day 57	Skindex-16 is used for participants to rate skin conditions that have occurred within the previous week. It is a short 16-item patient-completed assessment that are classified into three domains: symptoms [four items, 1-4], emotions, [seven items, 5-11] and functioning [five items, 12-16]. All items are scored on a seven-point numerical analogue scales (0=never bothered to 6=always bothered). Each item is then transformed to a linear scale from 0 (never bothered) to 100 (always bothered), where higher the score = more severe in impairment. The total score is the average of all 16 items scores ranging from 0 [best Health Related Quality of Life (HRQoL)] to 96 (worst HRQoL), where higher score indicates worst quality of life.	Baseline, Day 57
Secondary	Change from Baseline in Skindex-16 Questionnaire Overall Score and Domain Scores (Symptoms, Emotions, and Functioning) at Day 113 in Participants who Receive 2 Treatment Courses	Skindex-16 is used for participants to rate skin conditions that have occurred within the previous week. It is a short 16-item patient-completed assessment that are classified into three domains: symptoms [four items, 1-4], emotions, [seven items, 5-11] and functioning [five items, 12-16]. All items are scored on a seven-point numerical analogue scales (0=never bothered to 6=always bothered). Each item is then transformed to a linear scale from 0 (never bothered) to 100 (always bothered), where higher the score = more severe in impairment. The total score is the average of all 16 items scores ranging from 0 [best Health Related Quality of Life (HRQoL)] to 96 (worst HRQoL), where higher score indicates worst quality of life.	Baseline, Day 113
Secondary	Cosmetic Outcome as Assessed by the Participant at Day 57	Cosmetic Outcome is rated on a 4-point scale as excellent (no or mild redness or change in pigmentation), good (moderate redness or change in pigmentation), fair (slight-to-moderate scarring, atrophy, or induration), and poor (extensive scarring, atrophy, or induration).	At Day 57
Secondary	Cosmetic Outcome as Assessed by the Investigator at Day 57	Cosmetic Outcome is rated on a 4-point scale as excellent (no or mild redness or change in pigmentation), good (moderate redness or change in pigmentation), fair (slight-to-moderate scarring, atrophy, or induration), and poor (extensive scarring, atrophy, or induration).	At Day 57
Secondary	Cosmetic Outcome in Participants who Receive 2 Treatment Courses, as Assessed by Participants at Day 113	Cosmetic Outcome is rated on a 4-point scale as excellent (no or mild redness or change in pigmentation), good (moderate redness or change in pigmentation), fair (slight-to-moderate scarring, atrophy, or induration), and poor (extensive scarring, atrophy, or induration).	At Day 113
Secondary	Cosmetic Outcome in Participants who Receive 2 Treatment Courses, as Assessed by Investigator at Day 113	Cosmetic Outcome is rated on a 4-point scale as excellent (no or mild redness or change in pigmentation), good (moderate redness or change in pigmentation), fair (slight-to-moderate scarring, atrophy, or induration), and poor (extensive scarring, atrophy, or induration).	At Day 113
Secondary	Treatment Satisfaction Questionnaire for Medications (TSQM) Transformed Total Scores at Day 57	The TSQM-14 is a participant-rated scale used to assess subjective satisfaction with medication. The TSQM-14 provided scores on 4 domains: effectiveness (questions 1 to 3) side effects (4 to 8), convenience (9 to 11), and global satisfaction (12 to 14). With the exception of item 4 (presence of side effects; yes or no), all items have five or seven responses, scored from one (least satisfied) to five or seven (most satisfied). Scores for each domain were transformed into a final score ranging from 0 to 100, with higher numbers indicating a higher level of satisfaction.	At Day 57
Secondary	TSQM Transformed Scores in Participants who Receive 2 Treatment Courses at Day 113	The TSQM-14 is a participant-rated scale used to assess subjective satisfaction with medication. The TSQM-14 provided scores on 4 domains: effectiveness (questions 1 to 3) side effects (4 to 8), convenience (9 to 11), and global satisfaction (12 to 14). With the exception of item 4 (presence of side effects; yes or no), all items have five or seven responses, scored from one (least satisfied) to five or seven (most satisfied). Scores for each domain were transformed into a final score ranging from 0 to 100, with higher numbers indicating a higher level of satisfaction.	At Day 113
Secondary	Local Tolerability Score at Specific Timepoints for Each Individual Sign	Local tolerability score is evaluated by the investigator in terms of presence and absence of erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration signs and its severity in the areas of body where medication is applied. These symptoms are assessed by using a 4-point scale of 0-3, where 0 (absent) and 3 (severe). The higher score indicates severe symptoms.	At Day 1, 8, 15, 29, 57, 64, 71, 85, and 113
Secondary	Maximum Local Tolerability Score in Treatment Course for Each Individual Sign	Maximum local tolerability score by treatment course for each individual sign (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) will be assessed. Local tolerability score for each signs are assessed by using a 4 - point scale of 0 - 3, where 0 = none and 3 = severe. The higher score indicates severe symptoms.	At Day 1, 8, 15, 29, 57, 64, 71, 85, and 113
Secondary	Time to Maximum Local Tolerability Score Observed in Treatment Course for Each Individual Sign	Time to maximum local tolerability score for erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration will be assessed. Maximum local tolerability score by treatment course for each individual sign (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) will be assessed. Local tolerability score for each signs are assessed by using a 4 - point scale of 0 - 3, where 0 = none and 3 = severe. The higher score indicates severe symptoms.	At Day 1, 8, 15, 29, 57, 64, 71, 85, and 113
Secondary	Local Tolerability Signs Composite Score at Specific Timepoints	Local tolerability signs composite score (0-18) at Specific Timepoints, defined as the sum of the scores graded from 0 (none) to 3 (severe) on all six individual tolerability sign categories (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) will be assessed. The higher score indicates severe symptoms.	At Day 1, 8, 15, 29, 57, 64, 71, 85, and 113
Secondary	Maximum Local tolerability Signs Composite Score in Treatment Course	Maximum local tolerability signs composite score (0-18) in treatment course, defined as the sum of the scores graded from 0 (none) to 3 (severe) on all six individual tolerability sign categories (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) will be assessed. The higher score indicates severe symptoms.	At Day 1, 8, 15, 29, 57, 64, 71, 85, and 113
Secondary	Time to Maximum Local Tolerability Signs Composite Score Observed in Treatment Course	Time to maximum local tolerability signs composite score is observed in treatment course for each individual sign (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) will be assessed. Maximum local tolerability signs composite score (0-18) in treatment course, defined as the sum of the scores graded from 0 (none) to 3 (severe) on all six individual tolerability sign categories (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) will be assessed. The higher score indicates severe symptoms.	At Day 1, 8, 15, 29, 57, 64, 71, 85, and 113
Secondary	Number of Participants Showing Changes in Pigmentation and Scarring in the TF at Specific Timepoints	Absence or presence of pigmentation (that is, hypopigmentation and hyperpigmentation) and scarring in the TF will be assessed.	At Day 1, 8, 15, 29, 57, 64, 71, 85, and 113
Secondary	Number of Participants With Adverse Event (AE), Serious Adverse Events (SAEs) and Adverse Events of Special Interests (AESIs)	An AE is defined as any untoward medical occurrence in a clinical trial participant, regardless of the administration of the IMP and its causal relationship to it. unfavorable and unintended medical occurrence during the participant's participation in the trial, including deterioration of a pre-existing medical condition, an abnormal value in a laboratory assessment, or an abnormal finding in the physical examination. An SAE is any untoward medical occurrence that at any dose resulted in death; is life threatening; required persistent/significant disability/incapacity; resulted in initial or prolonged in participant hospitalization; is congenital anomaly/birth defect or otherwise considered medically important. AESIs included skin cancers [including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma] appearing within or outside the TF during the study.	From Screening up to Day 113
Secondary	Number of Participants With Clinically Significant Laboratory Abnormalities	Number of participants with clinically significant laboratory abnormalities (included hematology, blood chemistry and urinalysis) will be assessed. Clinically Significant Abnormal values will be determined by the investigator.	From Screening up to Day 113
Secondary	Number of Participants With Vital Signs Abnormalities	Number of participants with vital signs (including measurement of systolic and diastolic blood pressure, heart rate, respiratory rate, and tympanic temperature) will be assessed. Abnormal values will be determined by the investigator.	From Screening up to Day 113